Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo

Cancer Research

Volumn 62, Issue 19, 2002, Pages 5443-5450

  Ensor, Charles Mark ^a   Holtsberg, Frederick W ^a   Bomalaski, John S ^a   Clark, Mike A ^a  

^a Phoenix Pharmacologics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGININE; ARGININE DEIMINASE; ARGININOSUCCINATE LYASE; ARGININOSUCCINATE SYNTHASE; CITRULLINE; COMPLEMENTARY DNA; MACROGOL; MESSENGER RNA;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER CELL CARCINOMA; MELANOMA; MOUSE; MYCOPLASMA; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ARGININE; ARGININOSUCCINATE LYASE; ARGININOSUCCINATE SYNTHASE; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; HYDROLASES; LIVER NEOPLASMS; MELANOMA; MICE; MICE, NUDE; MICE, SCID; POLYETHYLENE GLYCOLS; RNA, MESSENGER; SUBSTRATE SPECIFICITY; SUCCINIMIDES; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036792124     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rogers, Q. R. Species variation in arginine requirements. In: Proceedings from a Symposium Honoring Willard J. Visek - from Ammonia to Cancer and Gene Expression, Special Publication 86. pp. 9-21. Urbana, IL: University of Illinois, 1994.
2. Takaku, H., Takase, M., Abe, S-I. Hayashi, H., and Miyazaki, K. In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini. Int. J. Cancer, 51: 244-249, 1992.
3. Takaku, H., Misawa, S., Hayashi, H., and Miyazaki, K. Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini. Jpn. J. Cancer Res., 84: 1195-1200, 1993.
4. Takaku, H., Matsumoto, M., Misawa, S., and Miyazaki, M. Anti-tumor activity of arginine deiminase from Mycoplasma arginini and its growth-inhibitory mechanism. Jpn. J. Cancer Res., 86: 840-846, 1995.
5. Miyazaki, K., Takaku, H., Umeda, M., Fujita, T., Huang, W., Kimura, T., Yamashita, J., and Horio, T. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line. Cancer Res., 50: 4522-4527, 1990.
6. Sugimura, K., Ohno, T., Fukuda, S., Wada, Y., Kimura, T., and Azuma I. Tumor growth inhibitory activity of a lymphocyte blastogenesis inhibitory factor. Cancer Res., 50: 345-349, 1990.
7. Sugimura, K., Ohno, T., Kusuyama, T., and Azuma, I. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro. Melanoma Res., 2: 191-196, 1992.
8. Holtsberg, F. W., Ensor, C. M., Bomalaski, J. S., and Clark, M. A. Formulation of arginine deiminase with polyethylene glycol (peg): effects of different linkers and molecular weight of PEG on the pharmacokinetics, pharmacodynamics and immunogenicity of this enzyme. J. Controlled Release. 80: 259-271, 2002.
9. Misawa, S., Aoshima, M., Takaku, H., Matsomoto, M., and Hayashi, H. High-level expression of Mycoplasma arginine deiminase in Escherichia coli and its efficient renaturation as an anti-tumor enzyme. J. Biotechnol., 36: 145-155, 1994.
10. Viau, A. T., Abuchowski, A., McCoy, J. R., Kazo. G. M., and Davis, F. F. Toxicologic studies of a conjugate of asparaginase and polyethylene glycol in mice, rats and dogs. Am. J. Vet. Res., 47: 1398-1401, 1986.
11. Miller, H. K., Salser, J. S., and Balis, M. E. Amino acid levels following L-asparagine amidohydrolase (EC. 3.5.1.1) therapy. Cancer Res., 29: 183-194, 1969.
12. Asselin, B. L. The three asparaginases: comparative pharmacology and optimal use in childhood leukemia. In: Kaspers, G. J. L., Pieters, R., and Veerman, A. J. P. (eds.), Drug Resistance in Leukemia and Lymphoma III, pp. 621-629. New York: Kluwer Academic/Plenum Press, 1999.
13. Muller, H. J., and Boos, J. Use of L-asparaginase in childhood ALL. Crit. Rev. Oncol. Hematol., 28: 97-113, 1998.
14. Jones, J. B. The Effect of Arginine Deiminase on Murine Leukemia Lymphoblasts (Ph.D. dissertation). Oklahoma City, OK: University of Oklahoma, 1981.
15. Moyer, G. H., and Pitot, H. C. Static and dynamic aspects of amino acid pools in rat liver and Morris hepatomas 9618A and 7800. Cancer Res., 34: 2647-2653, 1974.
16. Durden, D. L., and Distasio, J. A. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes. Cancer Res., 40: 1125-1129, 1980.
17. Gong, H., Zolzer, F., von Recklinghausen, G., Rossler, J., Breit, S., Havers, W., Fotsis, T., and Schweigerer, L. Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem. Biophys. Res. Commun., 261: 10-14, 1999.
18. Gong, H., Zölzer, F., von Recklinghausen, G., Havers, W., and Schweigerer, L. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia (Baltimore), 14: 826-829, 2000.
19. Scott, L., Lamb, J., and Wheatley, D. N. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br. J. Cancer, 83: 800-810, 2000.